A Japanese Phase 1/2 Study to Assess the Efficacy, Safety and Pharmacokinetics of Romidepsin in Patients With Peripheral T-cell Lymphoma (PTCL)

Lymphoma, T-cell, Peripheral Clinical Trial

Official title:

A Japanese Phase 1/2, Multicenter, Open-label Study to Assess the Efficacy, Tolerability, Safety and Pharmacokinetics of Romidepsin in Subjects With the Progressive or Relapsed Peripheral T-cell Lymphoma

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01456039
• Other study ID #: ROMI-TCL-001
• Status: Completed
• Phase: Phase 1/Phase 2
• Start date: December 1, 2011
• Est. completion date: December 14, 2018

Study information

• Verified date: January 2019
• Source: Celgene
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of the study was to assess efficacy, tolerability, safety and pharmacokinetics of Romidepsin in subjects with progressive or relapsed peripheral T-cell lymphoma

Description:

This is a Phase 1/2, non-randomized, open-label, single-arm trial with two phases. The first phase is a 3 + 3 dose escalation phase to determine a recommended dose for treating patients with Peripheral T-Cell Lymphoma (PTCL) or Cutaneous T-Cell Lymphoma (CTCL) based on the assessment of Dose Limiting Toxicities (DLTs).The second phase will assess efficacy at the recommended dose by measuring objective response [Complete Response (CR), Unconfirmed Complete Response (CR(u)) or Partial Response (PR)] and determining best overall response of each patient. Phase 1 will enroll a maximum of 12 patients and Phase 2 will enroll up to approximately 40 patients

Recruitment information / eligibility

• Status: Completed
• Enrollment: 51
• Est. completion date: December 14, 2018
• Est. primary completion date: July 28, 2015
• Accepts healthy volunteers: No
• Gender: All
• Age group: 20 Years and older

Eligibility

Inclusion Criteria:

Patients must fulfill all of the following criteria to be eligible for study participation and have:

• Histologically confirmed Peripheral T cell Lymphoma (PTCL) Not Otherwise Specified (NOS), Angioimmunoblastic T-cell Lymphoma, enteropathy- type T-cell lymphoma, subcutaneous panniculitis-like T-cell lymphoma, cutaneous T-cell lymphoma (excludes mycosis fungoides or Sezary syndrome) , hepatosplenic T-cell lymphoma, Anaplastic Large cell lymphoma (ALCL) [anaplastic lymphoma kinase-1 (ALK-1) negative], patients with ALK 1 expressing ALCL (ALK-1 positive) who have relapsed disease after Autologous Stem-Cell Transplantation, Transformed mycosis fungoides (MF), or Sézary syndrome (SS);

• Age =20 years;

• Written informed consent;

• Progressive Disease following at least one systemic therapy or refractory to at least one prior systemic therapy;

• Eastern Cooperative Oncology Group (ECOG) performance status of 0-2;

• Sufficient functions of bone marrow or other organs as evidenced by

• Hemoglobin =8.0 g/dL (The value after the 7th day of transfusion)

• Absolute neutrophil count (ANC) =1.0×10^9/L (The value after the 7th day of G-CSF)

• Platelet counts =100 x 10^9/L, or, if bone marrow infiltration is recognized, =75 ×10^9/L

• Total bilirubin (Total-Bil) =2 x upper limit of normal (ULN) (=3.0 x ULN in the presence of demonstrable liver metastasis)

• Aspartate Aminotransferase (AST)/Serum Glutamic-Oxaloacetic Transaminase (SGOT) =2 x Upper Limit Normal (ULN) (=3.0 x ULN in the presence of demonstrable liver metastasis)

• Alanine Aminotransferase (ALT)/Serum Glutamic-Oxaloacetic Transaminase (SGOT) =2 x ULN (=3.0 x ULN in the presence of demonstrable liver metastasis)

• Serum creatinine = 2 x ULN

• Serum potassium = lower limit of normal (LLN) and magnesium

• Patients for whom at least 1 measurable lesion is confirmed in the lesion assessment before enrollment; and

• Negative urine or serum pregnancy test on females of childbearing potential.

Exclusion Criteria: Confirmation should be made before enrollment, and the subjects corresponding to the criteria should not be enrolled.

1. Subjects in whom central nervous lymphoma is recognized during the screening period (If brain metastasis is suspected clinically, CT should be performed.)

2. Subjects undergoing chemotherapy or immunotherapy for the purpose of treatment of the target disease within 22 days before C1D1 (including C1D1) (using antibody drugs only within 3 months before C1D1)

3. Subjects receiving local application of steroids within 15 days before C1D1 (including C1D1) Use of steroids for the purpose other than that of treatment of the target disease should be allowed (Only CTCL subjects)

4. Subjects receiving systemic application of steroids within 22 days before C1D1 (including C1D1) (It is acceptable to continue the use of the steroid for the purpose of treatment of the target disease,which administered in doses = 10mg/day prednisolone or equivalent dose of other glucocorticoid. However increase of steroid dose cannot be allowed during the study period)

5. Subjects undergoing radiation therapy, PUVA therapy or TSEB for the purpose of treatment of the target disease within 22 days before C1D1 (including C1D1)

6. Subjects using other investigational products within 22 days before C1D1 (including C1D1) (using antibody drugs only within 3 months before C1D1)

7. Subjects undergoing blood transfusion and using G-CSF within 8 days before C1D1 (including C1D1)

8. Subjects with the following abnormalities in the cardiac function

1. Congenital QT prolongation syndrome

2. QTc interval >480 msec

3. Myocardial infarction within 6 months before C1D1. Subjects with a history of myocardial infarction between 6 and 12 months prior to C1D1 who are asymptomatic and have had a negative cardiac risk assessment (treadmill stress test, nuclear medicine stress test, or stress echocardiogram) since the event may occur

4. Significant ECG abnormalities including atrio-ventricular (AV) block type II, 3rd degree AV block, or bradycardia (ventricular rate less than 50 beats/min)

5. Symptomatic coronary artery disease (CAD) (e.g., Angina Canadian Class II-IV).

6. An ECG recorded at screening showing significant ST depression (ST depression of =2 mm, measured from isoelectric line to the ST segment at a point 60 msec at the end of the QRS complex). If there is any doubt, the subject should have a stress imaging study and, if abnormal, angiography to define whether or not CAD is present.

7. Congestive heart failure (CHF) that meets New York Heart Association (NYHA) Class II to IV definitions and/or ejection fraction <40% by MUGA scan or <50% by echocardiogram and/or MRI

8. A known history of sustained ventricular tachycardia (VT), ventricular fibrillation (VF), torsade de pointes, or cardiac arrest unless currently addressed with an automatic implantable cardioverter defibrillator (AICD)

9. Hypertrophic cardiomyopathy or restrictive cardiomyopathy from prior treatment or other causes (if there is any doubt, see ejection fraction criteria above)

10. Uncontrolled hypertension, i.e., systolic blood pressure (BP) is greater than or equal to 160 mmHg or diastolic BP is greater than or equal to 95 mmHg; subjects who have a history of hypertension controlled by medication must be on a stable dose (for at least one month)

11. Subjects with cardiac arrhythmia requiring an anti-arrhythmic drug

9. Concomitant use of a drug which may induce significant QT prolongation (refer to 9.2. Prohibited Concomitant Medications and Procedures.)

10. Concomitant use of strong or moderate CYP3A4 inhibitors which include grapefruit juice

11. Concomitant use of CYP3A4 inducers which include St John's Wort (1st step only)

12. Concomitant use of therapeutic warfarin which has a potential drug interaction. Use of a small dose of warfarin or other anticoagulant agent to maintain patency of venous access port and cannulas is permitted.

13. Clinically important active infections

14. Known infection with human immunodeficiency virus (HIV) antibody positive, HBs antigen positive or HCV antibody positive. If negative for HBsAg but HBcAb and/or HBsAb positive status, a HBV DNA test will be performed and if positive the subject will be excluded.

15. Subjects undergoing a wide range of radiation therapy in =30% of the bone marrow (such as all parts of the pelvic area or a half of the spinal cord) in the past. The subjects undergoing systemic radiation (including systemic electron therapy) as previous treatment for ASCT will be excluded.

16. Subjects undergoing a surgery within 15 days before C1D1 (including C1D1); however, even if more than 15 days have passed since the surgery, subjects without evidence of wound healing will be excluded.

17. Subjects who are during recovery process from severe wound or fracture.

18. Subjects with a history of allogeneic stem cell transplantation

19. Patients who are breast-feed during period of the IP administration or within 28 days after the end of the IP administration.

20. Subjects with a history of any other malignant tumor or solid cancer within previous 3 years (excluding basal or squamous cell carcinoma of skin, and in situ carcinoma of the cervix (CIN3) that has been treated curatively)

21. Subject with a history of hematological malignant tumor (other than T-cell lymphoma)

22. Subjects for whom transfusion of red blood cells or platelets is impossible (such as clinical state and religious beliefs)

23. Significant medical or psychiatric situation by which all of the study procedures may not be observed

24. Subjects receiving romidepsin in the past (Other HDAC inhibitors are acceptable)

25. Subjects judged to be inappropriate for this study by the investigator or sub-investigator.

26. Concomitant use of rifampicin.

Related Conditions & MeSH terms

• Lymphoma
• Lymphoma, T-Cell
• Lymphoma, T-Cell, Peripheral

Intervention

Drug:
• Romidepsin
Intravenous dosing for 4 hours on Days 1, 8, and 15 of each 28-day cycle

Locations

Country	Name	City	State
Japan	National Cancer Center Hospital	Chuo	Tokyo
Japan	Kyushu University Hospital	Fukuoka
Japan	Chugoku Central Hospital	Fukuyamashi	Hiroshima
Japan	Tokai University School of Medicine	Isehara	Kanagawa
Japan	National Cancer Center Hospital East	Kashiwa	Chiba
Japan	Kumamoto University Hospital	Kumamoto
Japan	University hospital, Kyoto prefectural University of Medicine	Kyoto
Japan	Tohoku University Hospital	Miyagi
Japan	Nagoya City University Hospital	Nagoya	Aichi
Japan	Nagoya Daini Red Cross Hospital	Nagoya	Aichi
Japan	Kochi Medical School Hospital	Nankoku	Kochi
Japan	Sapporo Hokuyu Hospital	Sapporo	Hokkaido
Japan	Sapporo Medical University Hospital	Sapporo	Hokkaido
Japan	Kinki University Hospital	Sayama	Osaka
Japan	Japanese Red Cross Medical Center	Shibuya	Tokyo
Japan	Ehime University Hospital	To-on	Ehime
Japan	The Cancer Institute Hospital of JFCR	Tokyo

Sponsors (1)

Lead Sponsor	Collaborator
Celgene

Country where clinical trial is conducted

Japan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Participants With Dose-limiting Toxicity (DLT) in Accordance With National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0 as Determined by the Efficacy and Safety Evaluation Committee (ESEC)	DLT was defined as an adverse event (AE) occurring in Cycle 1 in Phase 1 and judged that the causal relationship to the investigational product could not be denied. The severity of all AEs was graded based upon the NCI CTCAE version 3.0. DLTs were defined as: • Grade 4 Hemoglobin <6.5 g/dL • Grade 4 Neutrophil <500/µL continuing for at least 5 days • Febrile neutropenia (Grade 4 neutropenia caused by fever and = 38.5° C for more than 1 hour) • Grade 4 thrombocyte (< 25,000/µL), or thrombocytopenia with hemorrhage requiring platelet transfusion • Nausea, vomiting, or diarrhea at > grade 3 in spite of treatment • Grade 3 ALT (alanine aminotransferase) or AST (aspartate aminotransferase) values continued for 7 days. • Grade 4 ALT or AST • Grade 2 arrhythmia • Grade 4 non-hematological AEs • Other grade 3 non-hematological AEs except transient fatigue, anorexia, hyponatremia, and tumor lysis syndrome • Other AEs leading to discontinuation of administration	Up to Day 28; Cycle 1
Primary	Percentage of PTCL Participants With an Overall Best Response in Accordance With a Modified International Workshop Response Criteria (IWC) 1999 in Phase 2	Objective disease response in PTCL was defined as patients with a complete response (CR), unconfirmed complete response (CRu) or a partial response (PR) according to modified IWC 1999 criteria and assessed by an independent efficacy reviewer. A CR is >75% decrease in size of maximum 6 largest target within nodal and extranodal lesions, complete disappearance of other nodal and extranodal; total disappearance of clinical disease; disease-related signs and symptoms, normalization of biochemical abnormalities, disappearance of spleen, liver, or kidney enlargement; no bone marrow (BM) involvement, no new sites of disease. CRu: all above criteria fulfilled except for BM involvement is indeterminate. PR: a =50% decrease in size of 6 largest target lesions and no increase other nodal and extranodal; no progression of clinical disease; disease-related signs and symptoms, normalization or biochemical abnormalities, no progression in size of liver, spleen, or kidney; and no new sites of disease	Tumor assessments performed every 2 months; median follow-up time was 100 days; up to the data cut-off of 28 July 2015
Secondary	Participants With Treatment-Emergent Adverse Events (TEAEs) Associated With Romidepsin	An adverse event (AE) is any noxious, unintended, or untoward medical occurrence that may appear or worsen during the course of a study. An AE that resulted in any of the outcomes was defined as a serious (SAE): • Death • Life-threatening event • An inpatient hospitalization or prolongation of existing hospitalization • Persistent or significant disability or incapacity; • Congenital anomaly or birth defect • Other important medical event The investigator judged the relationship of an AE to study drug based on the timing of the AE relative to drug administration and whether or not other drugs, therapeutic interventions, or underlying conditions could provide an explanation for the event. The severity of an AE was evaluated by the investigator according to Common Terminology Criteria for Adverse Events (CTCAE Version 3.0), Japanese Clinical Oncology Group (JCOG) where Grade 1 = Mild, Grade 2 = Moderate, Grade 3 = Severe, Grade 4 = Life-threatening and Grade 5 = Death.	Day 1 of study drug through 30 days after the last dose of study drug or discontinuation date; Up to data cut-off of 28 July 2015; maximum follow up time was 184.3 weeks
Secondary	Area Under the Plasma Concentration-time Curve From Time Zero to the Last Measurable Concentration (AUC0-t) of Romidepsin in Phase 1	Area under the plasma concentration-time curve from time zero to the last quantifiable time point, calculated by the linear trapezoidal rule when concentrations are increasing and the logarithmic trapezoidal method when concentrations are decreasing.	Day 1 at Cycle 1; collected at 0 (pre-dose), 1, 2, 3, and 4 (at the end of administration) hours after the start of administration, 0.25 (15 minutes), 0.5 (30 minutes), 1, 2, 4, 6, 20, and 44 hours after the end of administration
Secondary	Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC8) of Romidepsin in Phase 1	Area under the plasma concentration-time curve from time zero extrapolated to infinity (AUC8) of romidepsin on Day 1; if possible the area under the concentration-time curve from time zero to infinity, calculated by the linear trapezoidal rule and extrapolated to infinity was calculated according to the following equation: AUC8 = AUCt + (Ct/ ?z ), where Ct is the last quantifiable concentration.	Day 1 at Cycle 1; collected at 0 (pre-dose), 1, 2, 3, and 4 (at the end of administration) hours after the start of administration, 0.25 (15 minutes), 0.5 (30 minutes), 1, 2, 4, 6, 20, and 44 hours after the end of administration
Secondary	Maximum Plasma Concentration (Cmax) of Romidepsin in Phase 1	The maximum observed plasma concentration of romidepsin (Cmax) obtained directly from the observed concentration versus time data	Day 1 at Cycle 1; collected at 0 (pre-dose), 1, 2, 3, and 4 (at the end of administration) hours after the start of administration, 0.25 (15 minutes), 0.5 (30 minutes), 1, 2, 4, 6, 20, and 44 hours after the end of administration
Secondary	Time to Maximum Plasma Concentration of Romidepsin (Tmax) in Phase 1	The time to first maximum observed plasma concentration of romidepsin after a single dose on Day 1.	Day 1 at Cycle 1; collected at 0 (pre-dose), 1, 2, 3, and 4 (at the end of administration) hours after the start of administration, 0.25 (15 minutes), 0.5 (30 minutes), 1, 2, 4, 6, 20, and 44 hours after the end of administration
Secondary	Terminal Phase Half-life of Romidepsin (t½) in Phase 1	The terminal phase half-life of romidepsin after a single dose on Day 1, calculated according to the following equation: t½ = 0.693/?z, where ?z is the terminal phase rate constant.	Day 1 at Cycle 1; collected at 0 (pre-dose), 1, 2, 3, and 4 (at the end of administration) hours after the start of administration, 0.25 (15 minutes), 0.5 (30 minutes), 1, 2, 4, 6, 20, and 44 hours after the end of administration.
Secondary	Apparent Total Clearance of Romidepsin (CL/F) of Romidepsin in Phase 1	The apparent total clearance of romidepsin after a single dose on Day 1, calculated as dose/AUC0-infinity.	Day 1 at Cycle 1; collected at 0 (pre-dose), 1, 2, 3, and 4 (at the end of administration) hours after the start of administration, 0.25 (15 minutes), 0.5 (30 minutes), 1, 2, 4, 6, 20, and 44 hours after the end of administration.
Secondary	Apparent Volume of Distribution (Vz/F) of Romidepsin in Phase 1	Apparent volume of distribution, was calculated according to the equation: Vd/F = (CL/F)/?z	Day 1 at Cycle 1; collected at 0 (pre-dose), 1, 2, 3, and 4 (at the end of administration) hours after the start of administration, 0.25 (15 minutes), 0.5 (30 minutes), 1, 2, 4, 6, 20, and 44 hours after the end of administration
Secondary	AUC0-t, at Steady State (ss) of Romidepsin in Phase 1 at Cycle 1, Day 15	Area under the plasma concentration-time curve from time zero to the last quantifiable time point at steady state, calculated by the linear trapezoidal rule when concentrations are increasing and the logarithmic trapezoidal method when concentrations are decreasing	Day 15 at Cycle 1; collected at 0 (pre-dose), 1, 2, 3, and 4 (at the end of administration) hours after the start of administration, 0.25 (15 minutes), 0.5 (30 minutes), 1, 2, 4, 6, 20, and 44 hours after the end of administration
Secondary	Cmax, ss of Romidepsin in Phase 1 at Cycle 1, Day 15	Maximum observed concentration in plasma at steady state	Day 15 at Cycle 1; collected at 0 (pre-dose), 1, 2, 3, and 4 (at the end of administration) hours after the start of administration, 0.25 (15 minutes), 0.5 (30 minutes), 1, 2, 4, 6, 20, and 44 hours after the end of administration
Secondary	Tmax,ss of Romidepsin in Phase 1 at Cycle 1, Day 15	Observed time to first maximum plasma concentration at steady state	Day 15 at Cycle 1; collected at 0 (pre-dose), 1, 2, 3, and 4 (at the end of administration) hours after the start of administration, 0.25 (15 minutes), 0.5 (30 minutes), 1, 2, 4, 6, 20, and 44 hours after the end of administration
Secondary	Terminal Phase Half-life of Romidepsin (t½) in Phase 1 at Cycle 1, Day 15	The terminal phase half-life of romidepsin after a single dose on Day 15, calculated according to the following equation: t½ = 0.693/?z, where ?z is the terminal phase rate constant.	Day 15 at Cycle 1; collected at 0 (pre-dose), 1, 2, 3, and 4 (at the end of administration) hours after the start of administration, 0.25 (15 minutes), 0.5 (30 minutes), 1, 2, 4, 6, 20, and 44 hours after the end of administration.
Secondary	AUC0-t, Accumulation Ratio of Romidepsin in Phase 1, Cycle 1	Area under the plasma concentration-time curve from time zero to the last quantifiable time point; accumulation ratio calculated as AUC (0-t),ss/AUC (0-t)	Day 1 and Day 15 in Cycle 1; collected at 0 (pre-dose), 1, 2, 3, and 4 (at the end of administration) hours after the start of administration, 0.25 (15 minutes), 0.5 (30 minutes), 1, 2, 4, 6, 20, and 44 hours after the end of administration
Secondary	Cmax Accumulation Ratio of Romidepsin in Phase 1, Cycle 1	Cmax of Romidepsin: accumulation ratio based on Cmax calculated as Cmax,ss/Cmax	Day 1 and Day 15 in Cycle 1; collected at 0 (pre-dose), 1, 2, 3, and 4 (at end of administration) hours after the start of administration, 0.25, 0.5, 1, 2, 4, 6, 20, and 44 hours after the end of administration. Day 8, Cycle 1, samples collected at 0 hour
Secondary	The Percentage of Participants With Abnormal Q-wave and T Wave Intervals	The time from the start of the Q-wave to the end of the T-wave QTc intervals greater than 450 msec post-baseline performed by centralized reviewer. The Bazett's (QTcB) and Fridericia (QTcF) correction were used as the standard clinical correction for calculating the heart rate-corrected QTc interval	Median follow-up: 100 days; up to data cut-off of 28 July 2015
Secondary	Percentage of PTCL Participants With the Best Response in Accordance With the Modified 2007 International Workshop Response Criteria as Assessed by IER	Objective disease response in PTCL was defined as achieving a CR or PR based on the Modified 2007 IWC. A CR = a complete disappearance of all disease; lymph node mass regression to normal size on computerized tomography (CT) scan or negative on positron emission tomography (PET); non-palpable splenic and disappearance of liver nodules; infiltrate cleared on repeat bone marrow (BM), immunohistochemistry negative. PR = a reduction of measurable lesions; = 50% decrease in sum of the products of the greatest diameters (SPD) of up to 6 largest dominant masses, no enlargement in size of other nodes; = 50% decrease in SPD and no increase in liver or spleen.	Tumor assessments performed every 2 months; median follow-up time was 100 days; up to the data cut-off of 28 July 2015
Secondary	Time to Response (TTR) for PTCL Participants With at Least a PR Based on the Modified 1999 IWC as Assessed by IER	TTR for PTCL was defined as the time in days from first dose date to the first date of objective disease response.	Median follow-up time was 100 days; up to the data cut-off of 28 July 2015
Secondary	Time to Response (TTR) for PTCL Participants With at Least a PR Based on the Modified 2007 IWC as Assessed by IER	TTR for PTCL was defined as the time in days from first dose date to the first date of objective disease response.	Median follow-up time was 100 days; up to the data cut-off of 28 July 2015
Secondary	Kaplan Meier Estimate of Duration of Response (DOR) for PTCL Responders Based on the Modified 1999 IWC as Assessed by the IER.	DOR was defined as the number of days from the date of the first disease response (Complete, Unconfirmed Complete or Partial Response) until the date of progression, analyzed using Kaplan-Meier methods.	Median follow-up time was 100 days; up to the data cut-off of 28 July 2015
Secondary	Kaplan Meier Estimate of Duration of Response (DOR) for PTCL Responders Based on the Modified 2007 IWC as Assessed by the IER.	DOR was defined as the number of days from the date of the first disease response (Complete, Unconfirmed Complete or Partial Response) until the date of progression, analyzed using Kaplan-Meier methods.	Median follow-up time was 100 days; up to the data cut-off of 28 July 2015
Secondary	Kaplan Meier Estimate of Time to Progression (TTP) in PTCL Participants Based on the 1999 IWC as Assessed by IER	Time to progression (=50% increase from the nadir in the individual sum of the products of the diameters of any index lesion; the reappearance of pathology, enlargement of liver/spleen, or unequivocal progression of non-measurable disease or appearance of any new lesions) was defined as the duration from the date of the first study drug dose to the date of relapse or progression	Median follow-up time was 100 days; up to the data cut-off of 28 July 2015
Secondary	Kaplan Meier (K-M) Estimate of Time to Progression (TTP) in PTCL Participants Based on the Modified 2007 IWC as Assessed by IER	Time to progression (=50% increase from the nadir in the individual sum of the products of the diameters of any index lesion; the reappearance of pathology, enlargement of liver/spleen, or unequivocal progression of non-measurable disease or appearance of any new lesions) was defined as the duration from the date of the first study drug dose to the date of relapse or progression	Median follow-up time was 100 days; up to the data cut-off of 28 July 2015